Incyte — Jul 28, 2026 release

Total GAAP R&D and SG&A operating expense guidance is $4,915 - $4,995 million and total non-GAAP R&D and SG&A operating expense guidance is $4,625 - $4,695 million. The revised guidance reflects the impact of the acquisition of Vega Therapeutics, including an IPR&D expense of approximately $1,270 million expected in the third quarter 2026 associated with the upfront payment and related transaction costs, as well as $50 million of incremental ongoing R&D investments related to the development of latarcibart. The transaction upfront payment is expected to result in an IPR&D expense reflected in the third quarter and full year 2026 GAAP and non-GAAP financial results. Incyte’s guidance for the fiscal year 2026 is summarized below. Current Previous Total net sales $5,130 - $5,260 million $4,770 - $4,940 million Jakafi net sales (1) unchanged $3,220 - $3,270 million Opzelura net sales (2) $1,050 - $1,100 million $750 - $790 million Hematology and Oncology net sales (3) $860 - $890 million $800 - $880 million Total GAAP R&D and SG&A operating expenses (4) $4,915 - $4,995 million $3,495 - $3,675 million Total Non-GAAP R&D and SG&A operating expenses (4,5) $4,625 - $4,695 million $3,205 - $3,375 million 1 Includes Jakafi XR ™ (ruxolitinib) net sales. 2 Includes net sales for moderate atopic dermatitis in Europe, which is anticipated to be approved in the second half of 2026. 3 Includes Pemazyre ® (pemigatinib) in the U.S., Canada, Europe, Japan, Asia Pacific (APAC), Middle East and Africa